Protocol for LGV Enhanced Surveillance

Lymphogranuloma venereum (LGV) in Canada: Recommendations for Diagnosis and Treatment and Protocol for National Enhanced Surveillance

[Back] [Table of Contents] [Next]

Summary

In light of recent LGV cases reported internationally, an enhanced surveillance system for LGV was initiated by the Public Health Agency of Canada in partnership with the provinces and territories in February 2005. The following describes the working case definition for this LGV enhanced surveillance system.

Working Case Definition

Probable Case

Positive C. trachomatis culture, NAAT* or serology (MIF >= 1:256, CF >= 1:64) PLUS

Proctitis OR
Inguinal/femoral lymphadenopathy OR
Sexual partner with LGV

Confirmed Case

DNA sequencing OR RFLP for C. trachomatis confirming serovars of L1, L2, or L3 present.

Cases which fit a probable case definition but test negative for LGV serovars on confirmatory (genotype) testing are not considered probable cases; cases which fit a probable case definition and whose test results are inconclusive on confirmatory (genotype) testing are considered probable cases.

All probable or confirmed cases should be reported by local public health authorities to the appropriate regional and provincial/territorial authorities. The provinces and territories have agreed to report LGV to the Sexual Health and STI Section of the Public Health Agency of Canada at (613) 946-8637.

Once cases of LGV are reported to the Public Health Agency of Canada, PHAC will be responsible for collating and analyzing the data from the enhanced surveillance program and will include this analysis within quarterly reports posted on our Web site.

An LGV enhanced surveillance form is attached below in Appendix I. This guide is intended to serve as a helpful tool for healthcare professionals in collecting key epidemiological information on suspected cases.

[Back] [Table of Contents] [Next]